Cerner acquires behavioral health tech firm

| | Health Exec | Digital Transformation

Cerner has reached an agreement to acquire Anasazi Software, a developer of behavioral health technology, for an undisclosed sum.

The combination of Cerner Millennium, including inpatient behavioral health, and Anasazi’s community behavioral health solutions will create a offering and allow behavioral health providers access to data to aid in care transitions.

Anasazi has offered a technology line designed to provide an all-inclusive approach to behavioral health care for more than 20 years. Anasazi’s suite of technologies include an EHR, managed care technology, practice management/billing, cost accounting and e-prescribing systems as well as fiscal, human resource, assessment, treatment planning and progress noting components.

The acquisition is anticipated to close in November and is not expected to have a material impact on Cerner’s financial results.

Related Content

10 signs AI is ‘eating the world (of venture capital)’
From Capitol Hill to a hospital near you? 5 federal recommendations for healthcare AI policy
Healthcare AI regulation needs nuance, balance: Research review
ICU diary-keeping: There’s an AI for that
Stanford HAI lookback: Best-read blog posts of 2024
Providers, payers share actionable experiences involving healthcare AI

Around the web

Cardiovascular Business
FDA says years-long tirzepatide shortage is resolved, will give limited leeway to compounders

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

AI in Healthcare
From Capitol Hill to a hospital near you? 5 federal recommendations for healthcare AI policy

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Cardiovascular Business
Merck spends up to $2B to license new weight loss drug with potential heart benefits

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.